References
- Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, Oakley DH, et al. 2011. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 144(3):439–452.
- Cong L, Zhang F. 2015. Genome engineering using CRISPR-Cas9 system. Methods in Molecular Biology. 1239:197–217.
- Evans MJ, Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. Nature. 292(5819):154–156.
- Gazdic M, Volarevic V, Harrell CR, Fellabaum C, Jovicic N, Arsenijevic N, Stojkovic M. 2018. Stem cells therapy for spinal cord injury. International Journal of Molecular Sciences. 19(4): 1039
- Kucab JE, Hollstein M, Arlt VM, Phillips DH. 2017. Nutlin-3a selects for cells harbouring TP53 mutations. International Journal of Cancer. 140(4):877–887.
- Martin GR. 1981. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences of the United States of America. 78(12):7634–7638.
- Merkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S, Mekhoubad S, Ilic D, Charlton M, et al. 2017. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 545(7653):229–233.
- Millman JR, Xie C, Van Dervort A, Gurtler M, Pagliuca FW, Melton DA. 2016. Generation of stem cell-derived beta-cells from patients with type 1 diabetes. Nature Communications. 7:11463.
- Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. 2014. Generation of functional human pancreatic beta cells in vitro. Cell. 159(2):428–439.
- Przepiorski A, Sander V, Tran T, Hollywood JA, Sorrenson B, Shih JH, Wolvetang EJ, McMahon AP, Holm TM, Davidson AJ. 2018. A simple bioreactor-based method to generate kidney organoids from pluripotent stem cells. Stem Cell Reports. 11(2):470–484.
- Setoguchi K, TeSlaa T, Koehler CM, Teitell MA. 2016. P53 regulates rapid apoptosis in human pluripotent stem cells. Journal of Molecular Biology. 428(7):1465–1475.
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131(5):861–872.
- Tsankov AM, Akopian V, Pop R, Chetty S, Gifford CA, Daheron L, Tsankova NM, Meissner A. 2015. A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells. Nature Biotechnology. 33(11):1182–1192.
- Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303(5659):844–848.
- Waters CM, Littlewood TD, Hancock DC, Moore JP, Evan GI. 1991. c-myc protein expression in untransformed fibroblasts. Oncogene. 6(5):797–805.